Leading global pharmaceutical products by projected sales 2026

Keytruda, a pharmaceutical product owned by Merck & Co, is forecast to generate around 27 billion U.S. dollars in sales in 2026. Other prominent pharmaceutical products, such as Eliquis and Opdivo, are also expected to do well that year. Biotech companies In 2020, Amgen was among the world’s top pure play biotech company, based on market capitalization. The American company had a total market cap of almost 130 billion U.S. dollars that year. In terms of R&D expenditure, Swiss company Roche led the 2019 rankings, spending over 11 billion U.S. dollars. BMS and Johnson & Johnson stood in second and third place and spent a total of 9.4 billion and 8.8 U.S. dollars on research and development combined that year, respectively. Gilead Sciences Gilead Sciences, which is headquartered in California, United States, generated 24.7 billion U.S. dollars of revenue in 2020. Gilead Sciences’ top product was Biktarvy, which made 29 percent of the company’s total revenue in 2020.

默克公司旗下药物Keytruda预计在2026年可实现约270亿美元的销售额。其他知名制药产品，如Eliquis和Opdivo，亦预期在当年表现出色。在2020年，根据市值计算，安进公司（Amgen）位列全球领先的纯生物科技企业之一。该公司当年总市值为约1300亿美元。就研发投入而言，瑞士罗氏公司（Roche）在2019年排名第一，投入研发资金超过110亿美元。百时美施贵宝（BMS）和强生（Johnson & Johnson）分别位列第二和第三，当年研发投入总额分别为94亿美元和88亿美元。总部位于美国的吉利德科学公司（Gilead Sciences）在2020年创造了247亿美元的营收。该公司最畅销的产品为Biktarvy，2020年该产品为公司总营收贡献了29%。” }